Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Niche and Rare Solid Tumors (Navigating Reimbursement and Maximizing Market Access) | Physician & Payer Forum | EU5 | 2015
A Survey of Medical Oncologists and Interviews with Payers in the EU5 Hepatocellular carcinoma (HCC), thyroid cancer, gastrointestinal stromal tumor (GIST), and neuroendocrine tumors (NETs) fall…
What Are the U.S. Market Access Levers and Hurdles Facing Orally Administered, Small-Molecule Targeted Oncology Drugs for Renal Cell Carcinoma and Hepatocellular Carcinoma? | Physician & Payer Forum | US| 2015
A Survey of Medical Oncologists and Managed Care Organization Pharmacy and Medical Directors The hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) markets differ with respect to…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Physician & Payer Forum | US | 2015
How Will U.S. Payer and Prescriber Attitudes Shape This Competitive Market? The treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL…
Current and Emerging Small-Molecule Targeted Agents in Key Oncology Indications | Physician & Payer Forum | Brazil and Mexico | 2015
Securing Market Share and Payer Acceptance in Increasingly Crowded and Segmented Markets in Brazil and Mexico Small molecule therapies offer specific targeting of the aberrant cellular…
Current and Emerging Small-Molecule Targeted Agents for NSCLC | Physician & Payer Forum | US | 2015
A Survey of Oncologists and MCO Pharmacy and Medical Directors Targeted small-molecule agents have emerged as key treatment options for biomarker-defined non-small-cell lung cancer (NSCLC)…
The Impact of Biosimilars in NHL, Breast Cancer, and Colorectal Cancer | Physician & Payer Forum | Brazil and Mexico | 2015
Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (NHL), colorectal…
Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Brazil for Breast Cancer, NSCLC, CRC, and Malignant Melanoma | Physician & Payer Forum | Brazil and Mexico | 2014
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Brazil is highly dependent on incorporation into…
Oncology (Securing Favorable Reimbursement Status in the EU5 Oncology Markets: Evolving Physician and Payer Perspectives on Biomarker-Driven Prescribing in Oncology) | Physician & Payer Forum | EU5 | 2014
As oncology increasingly moves toward personalized approaches to therapy, the use of predictive biomarkers will become more important. A plethora of biomarker-driven brands are already available…
Granulocyte Colony-Stimulating Factors and Monoclonal Antibodies in Oncology (Physician Perspectives) | Biosimilars Advisory Service | US/Eu5/Japan | 2014
European oncologists have had high exposure to biosimilars compared with other European specialists owing to the availability of epoetin alfa and filgrastim biosimilars. Although no biosimilars are…
Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Mexico and Argentina for Breast Cancer, NSCLC, CRC and Malignant Melanoma | Physician & Payer Forum | Mexico and Argentina | 2014
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Mexico and Argentina is highly dependent on their…
